ESC Congress 2014 highlight podcasts

Leave a comment
Click any image to enlarge

Our latest podcasts feature the European Society of Cardiology (ESC) Congress held recently in Barcelona, Spain, and highlight our selection of trials, registry data and guideline updates that will change UK clinical practice.

Advertisement
Heart failure - BJC Learning programme
For healthcare professionals only

esc13-see-you-banner

esc13-see-you-banner

Professor Keith Fox, University of Edinburgh, and Chairman of the ESC Programme Committee, discusses:

• in heart failure – PARADIGM-HF and CONFIRM-HF
• in coronary artery disease – SIGNIFY, ATLANTIC, CULPRIT, MITOCARE, COMPLETE and TASTE
• in arrhythmia – X-VERT and STICS
• and in lipid lowering – ODYSSEY and SOLID-TIMI 52

View Keith Fox interview now
This podcast has been made possible by unrestricted educational grants from Bayer Healthcare (Job code L.GB.10.2014.8412; Date of preparation October 2014) and Sanofi/Regeneron (Job code SAGB.CMR.14.10.0599b)

esc13-see-you-banner

Dr Christopher Cannon, Harvard Clinical Research Institute, Boston, USA, discusses:

• The ODYSSEY programme, including ODYSSEY COMBO II
• Were there any adherence issues given that the PCSK9 monoclonal antibody therapies are injected subcutaneously?
• Current evidence on the danger of neurocognitive adverse effects
• Patient priorities for these treatments

View Christopher Cannon interview now
This podcast has been made possible by an unrestricted educational grant from Sanofi/Regeneron (Job code SAGB.CMR.14.10.0599a)

esc13-see-you-banner

Professor Kausik Ray, St George’s Hospital, University of London, puts these studies into clinical perspective, and explains why the extent of LDL cholesterol lowering is key in the prevention of cardiovascular disease, rather than the means of LDL cholesterol lowering, using:

• Insights from genetic and observational studies
• Insights from clinical trials
• And considering whether very low LDL-C levels are safe

View Kausik Ray interview now
This podcast has been made possible by an unrestricted educational grant from Sanofi/Regeneron (Job code SAGB.CMR.14.10.0599c)

THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT